Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Expected to Post Q1 2025 Earnings of ($0.47) Per Share

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Cartesian Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($0.47) for the quarter. HC Wainwright currently has a “Buy” rating and a $54.00 price target on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.52) EPS and Q4 2025 earnings at ($0.58) EPS.

RNAC has been the subject of a number of other research reports. Leerink Partnrs reaffirmed an “outperform” rating on shares of Cartesian Therapeutics in a research report on Tuesday. SVB Leerink began coverage on Cartesian Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $39.00 target price for the company. Finally, Needham & Company LLC started coverage on shares of Cartesian Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $42.00 price target on the stock.

Cartesian Therapeutics Price Performance

RNAC stock opened at $20.59 on Wednesday. Cartesian Therapeutics has a 1 year low of $11.66 and a 1 year high of $42.60. The firm has a fifty day simple moving average of $19.32.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its earnings results on Thursday, March 7th. The company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($0.30) by ($2.10). The business had revenue of $8.27 million during the quarter. Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%.

Insider Transactions at Cartesian Therapeutics

In other Cartesian Therapeutics news, Director Timothy A. Springer bought 21,612 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was purchased at an average price of $16.20 per share, for a total transaction of $350,114.40. Following the purchase, the director now directly owns 1,017,228 shares in the company, valued at $16,479,093.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have acquired 22,472 shares of company stock worth $365,981. Company insiders own 31.20% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee bought a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned 0.98% of Cartesian Therapeutics at the end of the most recent quarter. 86.95% of the stock is currently owned by institutional investors and hedge funds.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.